Prevention of serious lower resp tract disease caused by resp syncytial virus (RSV) in ped patients at high risk of RSV disease. Childn born at ≤35 wk of gestation & <6 mth at the onset of RSV season; <2 yr requiring treatment for bronchopulmonary dysplasia (BPD) w/in the last 6 mth; <2 yr w/ haemodynamically significant congenital heart disease.
IMChildn 15 mg/kg once a mth during anticipated periods of RSV risk in the community. Administer 1st dose prior to start of RSV season & subsequent doses given mthly throughout RSV season. Childn undergoing cardiac bypass Administer 15 mg/kg as soon as stable after surgery to ensure adequate palivizumab serum levels.
Allergic reactions including very rare anaphylaxis & anaphylactic shock. Discontinue use if severe hypersensitivity reaction occurs. Not indicated for adult usage. Patients w/ thrombocytopenia or any coagulation disorder. Moderate to severe acute infection or febrile illness. Pregnancy & lactation.
Sign Out
